Canadian medical device maker Trudell Medical International has reported positive results from a real-world retrospective study of its AeroChamber Plus Flow-Vu Anti-Static valved holding chamber (VHC) device in asthma patients.
According to the data, 18,000 patients experienced superior asthma control with Trudell’s VHC, when compared to other non-anti-static chambers.
AeroChamber Plus Flow-Vu chamber has been designed to enable the inhaler to deliver medicine to the right location of lungs. The chamber also decreases the amount of medication retained in the mouth to minimise the potential for side effects.
It comes with a dedicated inhalation indicator that provides a visual aid for correct use and medication delivery.
Out of the 8,586 patients followed-up for a minimum of 12 months during the study, those using AeroChamber Plus Flow-Vu are reported to have demonstrated delayed time to first exacerbation, while emergency room / accident and emergency (ER/A&E) visits decreased by 13% with this chamber.
Trudell Medical UK Europe regional head Dr Alan Clark said: “Our new AeroChamber Plus Flow-Vu Anti-Static VHC may reduce some of the 121,000 A&E attendances made by asthma patients every year in the UK. A 13% reduction may mean 15,730 fewer visits to A&E by asthma patients each year.”
Clark further added that according to their budget impact model, if all asthma patients who are using pMDI and VHC combination in the UK were switched to the AeroChamber Plus Flow-Vu Anti-Static VHC, £7.2m of healthcare resources per year can be relocated to other areas-of-need.
In a new in-vitro evaluation of VHC equivalence, Trudell’s Anti-Static VHC was found to be more effective in delivering the aerosolised drug, compared to various other anti-static VHCs.